1 Pill - Search News

News

Eli Lilly Vows to Make Weight-Loss Pill in U.S.

Money Morning · 18h

Weight Loss In a Pill Will Make Eli Lilly a $1 Trillion Stock

Pharmaceutical giant Eli Lilly (LLY) surged 14% last week to $840 per share following positive Phase 3 trial results for its oral weight-loss drug, orforglipron. With a market cap of $796 billion, LLY is the world’s most valuable healthcare company, and its trajectory suggests it could reach $1,000 per share or more by year-end 2025.

CBS News on MSN · 3d

Eli Lilly says GLP-1 pill for diabetes and weight loss effective in study, plans to seek FDA approval

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for diabetes and weight loss.

Fox News on MSN · 4d

First GLP-1 pill for weight loss, diabetes shows success in late-phase trial

Eli Lilly has seen positive results from a phase 3 trial of Orforglipron, the first-ever GLP-1 pill for weight loss and type 2 diabetes. Previous versions were administered via injection.

Scientific American23h

Ozempic Shots Have Taken Off. Why Haven’t GLP-1 Pills?

Some experts say oral versions of popular weight-loss drugs such as Wegovy could offer people more flexibility and ...

Medical Marketing & Media3d

Eli Lilly’s GLP-1 pill aces late-stage trial days after Pfizer pulls theirs

The pharma giant said its oral GLP-1 drug demonstrated significant efficacy results and a safety profile consistent with its ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results